Treatment, Rationale, and Study Design of TALISMAN Study: A Randomized Phase II Open-Label Study of Second-line Erlotinib Versus Intermittent Erlotinib Dosing With Docetaxel in the Treatment of Former-Smoker Men Affected by Recurrent Squamous Non–Small-Cell Lung Cancer
- 1 January 2011
- journal article
- research article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 12 (1), 70-73
- https://doi.org/10.3816/clc.2011.n.010
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology, 2009
- Schedule-Dependent Apoptosis in K-ras Mutant Non–Small-Cell Lung Cancer Cell Lines Treated with Docetaxel and Erlotinib: Rationale for Pharmacodynamic SeparationClinical Lung Cancer, 2007
- Treatment of Non-small Cell Lung Cancer, Stage IVSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2007
- Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation TrialJournal of Clinical Oncology, 2007
- Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21Clinical Lung Cancer, 2006
- TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2005
- Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to PaclitaxelClinical Cancer Research, 2005
- Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255Cancer Research, 2004